Clinical Trials Logo
  1. Home
  2. Neoplasms, Rectal
  3. NCT03671369

A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea

Neoplasms, Rectal Clinical Trial

Official title:
Post-marketing Surveillance of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix When Administered According to the Approved Prescribing Information in Korea

Clinical Trial Summary

The purpose of this post-marketing surveillance (PMS) study is to collect safety information on the use of Cervarix upon the expanded indication to anal cancer to both women and men (at least 600 Korean women and men) within 30 days after each vaccination dose, when administered according to the approved prescribing information (PI) in Korea in a real health care setting over a period of 4 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03671369
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase
Start date October 2, 2018
Completion date December 1, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03573791 - Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
Completed NCT02017509 - Immunoscore in Rectal Cancer
Recruiting NCT05723562 - A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Phase 2